ダウンロード数: 25

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
j.ensci.2021.100351.pdf896.29 kBAdobe PDF見る/開く
タイトル: A case of reversible cerebral vasoconstriction syndrome associated with anti-phospholipid antibody syndrome and systemic lupus erythematosus
著者: Shima, Atsushi  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-3068-4621 (unconfirmed)
Maki, Takakuni  kyouindb  KAKEN_id
Mimura, Naoya
Yamashita, Hirofumi
Emoto, Noriaki
Yoshifuji, Hajime
Takahashi, Ryosuke  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-1407-9640 (unconfirmed)
著者名の別形: 島, 淳
眞木, 崇州
三村, 直哉
山下, 博史
吉藤, 元
髙橋, 良輔
キーワード: Cilostazol
Lomerizine
Anti-phospholipid antibody syndrome
Reversible cerebral vasoconstriction syndrome
Endothelin-1
発行日: Sep-2021
出版者: Elsevier BV
誌名: eNeurologicalSci
巻: 24
論文番号: 100351
抄録: The pathomechanisms and treatment strategy for rare presentations of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS) remain to be determined. We report a 67-year-old woman with APS who presented with ischemic stroke due to RCVS. She was treated with low-dose cilostazol and lomerizine hydrochloride, which resulted in functional improvement and recovery of vasoconstriction within 12 weeks. Her plasma endothelin-1 level was decreased after relief of vasoconstriction, compared with the pre-treatment condition. Increased plasma endothelin-1 may be related to the underlying pathomechanism of RCVS with APS, against which cilostazol and lomerizine hydrochloride could be effective.
著作権等: © 2021 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license.
URI: http://hdl.handle.net/2433/276959
DOI(出版社版): 10.1016/j.ensci.2021.100351
PubMed ID: 34258413
出現コレクション:学術雑誌掲載論文等

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons